Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Neoadjuvant immunotherapy combined with radiochemotherapy vs chemotherapy alone in pMMR colon cancers: The TORCH-C randomized phase 2 clinical trial.

View Full Paper
Ask AI
Bookmark
Share

Authors

HZH X ZhangFudan University Shanghai Cancer CenterYLY LiShanghai Medical College of Fudan UniversityFXFan XiaFudan University Shanghai Cancer Center

Discussion

Loading...

Member takes

Implication

Randomized trial evaluates neoadjuvant immunotherapy and radiochemotherapy efficacy in high-risk pMMR colon cancers, suggesting a new treatment option.

Key Points

  • To assess the effectiveness of neoadjuvant immunotherapy combined with radiochemotherapy versus chemotherapy alone in patients with high-risk pMMR colon cancers.
  • Prospective, multicenter, randomized phase 2 trial
  • Enrolled 120 high-risk LACC patients
  • Primary outcome: pathological complete response (pCR) rate
  • pCR rate was 45.3% in the immunotherapy group compared to 10% in the chemotherapy group (P < 0.05)
  • Received surgery: 53 in group A and 50 in group B
  • Common adverse event: thrombocytopenia in 22.2% group A and 18.9% group B

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a192ee7fab5b468c44183ddhttps://doi.org/10.1200/jco.2026.44.16_suppl.3634
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant short-course radiotherapy combined with CAPOX and PD-1 inhibitor for MSS/pMMR high-risk locally advanced colon cancer: A randomized, prospective, multicentre, phase II trial (TORCH-C).2026
  2. 2Immunotherapy-based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Preliminary results of TORCH-iTNT.2026
  3. 3Neoadjuvant tislelizumab plus chemotherapy in MSS/pMMR high-risk locally advanced colon cancer: Updated analysis results from a phase 2 trial.2026
  4. 4Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)2024 · 132 citations
  5. 5Preoperative Strategies for Locally Advanced Colon Cancer2024 · 16 citations